Genotyping Influences Outcome of Coronary Artery Stenting

Korea University Anam Hospital5,000 enrolled

Overview

This study evaluated epidemiology and clinical outcome of clopidogrel related various genotyping in Korean patients who had undergone percutaneous coronary intervention as a all comer registry form.

This study evaluates the relationship between clopidogrel related various genotyping, epidemiology and clinical outcome of patient who had undergone percutaneous coronary intervention. Clopidogrel resistance was measured with VerifyNow, which is a device that can monitor platelet inhibition of clopidogrel. Genes which are known to be related with clopidogrel resistance were evaluated; (1-3) CYP 2C19 \*2, \*3, \*17, (4) PON1 Q192R, (5) ABCB1 3435C-\>T, (6) P2Y12, (7) CYP 2C9 \*3.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

5,000

Conditions

Myocardial Ischemia CLOPIDOGREL, POOR METABOLISM of (Disorder)

Interventions

ClopidogrelDRUG

Administration of conventional dual anti-platelet treatment (aspirin 100mg and clopidogrel 75mg daily) for minimum 3 months after percutaneous coronary intervention

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Written informed consent * Older than 20 years * All percutaneous coronary intervention patients within 1 month Exclusion Criteria: * Pregnancy * Life expectancy below 1 year * Known aspirin or clopidogrel allergy